What is claimed is:
1. An electronic device comprising a functional element chip having a photofunctional element formed thereon, a wiring member electrically connected to a terminal of the functional element chip, and an encapsulant for fixing the functional element chip and the wiring member,
wherein a light blocking member with an opening portion is provided on a front face side of the wiring member, and
wherein an end of the opening portion is located more inside than an inner end of the wiring member.
2. The electronic device according to claim 1, wherein the end of the opening portion and the inner end of the encapsulant are flush with each other.
3. The electronic device according to claim 1, wherein the encapsulant is formed of a photo-setting resin.
4. The electronic device according to claim 1, wherein the encapsulant is formed of a thermo-photo-setting resin.
5. The electronic device according to claim 1, comprising on a front face side of the functional element chip, a light transmissive protective member for protecting the photofunctional element.
6. The electronic device according to claim 1, wherein the light blocking member is light-absorptive.
7. The electronic device according to claim 1, wherein the encapsulant continuously surrounds the periphery of the functional element chip.
8. The electronic device according to claim 1, wherein the encapsulant covers a conductive beam lead of the wiring member that is connected to the functional element chip such that the beam lead is not exposed.
9. The electronic device according to claim 1, wherein the photofunctional element is at least one of a light receiving element and a light emitting element.
10. The electronic device according to claim 1, wherein the photofunctional element is a DMD.
11. The electronic device according to claim 1, wherein the area of the opening portion is larger than the area of a portion where the photofunctional element is disposed.
12. An electronic device comprising a semiconductor chip having an optical semiconductor element formed thereon, a wiring member electrically connected to a terminal of the semiconductor chip, an encapsulant for fixing the semiconductor chip and the wiring member, and a light transmissive protective member,
wherein a light blocking member with an opening portion is provided between a front face of the wiring member and a rear face of the protective member,
wherein an end of the opening portion is located more inside than an inner end of the wiring member, and
wherein the encapsulant is a photo-set resin, and the end of the opening portion and an inner end of the encapsulant align.
13. The electronic device according to claim 12, wherein the encapsulant is formed of a thermo-photo-setting resin.
14. The electronic device according to claim 12, wherein the light blocking member is light-absorptive.
15. The electronic device according to claim 12, wherein the encapsulant continuously surrounds the periphery of the semiconductor chip.
16. The electronic device according to claim 12, wherein the encapsulant covers a conductive beam lead of the wiring member that is connected to the semiconductor chip such that the beam lead is not exposed.
17. The electronic device according to claim 12, wherein the optical semiconductor element is at least one of a light receiving element and a light emitting element.
18. The electronic device according to claim 12, wherein the optical semiconductor element is a DMD.
19. The electronic device according to claim 12, wherein the area of the opening portion is larger than the area of a portion where the optical semiconductor element is disposed.
20. The electronic device according to claim 12, wherein the encapsulant is an epoxy resin.
21. A process of producing an electronic device comprising a functional element chip with a terminal, a wiring member electrically connected to the terminal, an encapsulant for fixing the functional element chip and the wiring member, and a light transmissive protective member, the process comprising the steps of:
disposing a light blocking member with an opening portion between a front face of the wiring member and a rear face of the protective member such that an end of the opening portion is located more inside than an inner end of the wiring member;
providing a photo-setting resin for forming the encapsulant onto the periphery of a connecting portion between the wiring member and the terminal of the functional element chip; and
irradiating a light from the side of a front face of the protective member through the opening portion of the light blocking member to set at least a part of the photo-setting resin.
22. The process of producing an electronic device according to claim 21, wherein the photo-setting resin is a thermo-photo-setting resin, further comprising the step of heating the thermo-photo-setting resin after the step of irradiating the light.
23. The process of producing an electronic device according to claim 21, further comprising the step of irradiating a light for setting the photo-setting resin from the side of a rear face of the wiring member.
24. The process of producing an electronic device according to claim 21, further comprising the step of bonding the wiring member and the terminal of the functional element chip to each other prior to the step of providing the photo-setting resin.
25. The process of producing an electronic device according to claim 21, further comprising the step of providing a layer for forming the light blocking member on the rear face of the protective member.
26. A process of producing an electronic device comprising a first substrate, a second, light transmissive substrate disposed apart from the first substrate, and an encapsulant for fixing the periphery of the first and the second substrates so as to fill a space between the first and the second substrates, comprising the steps of:
disposing a light blocking member with an opening portion on a rear face of the periphery of the second substrate;
disposing a photo-setting resin for forming the encapsulant on the periphery of the first and the second substrates; and
irradiating a light from the side of a front face of the second substrate through the opening portion of the light blocking member to set at least a part of the photo-setting resin.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating a subject with a hyperproliferative disease comprising administering to the subject an effective amount of a MEK inhibitor, wherein the hyperproliferative disease is related to the hyperactivity of MEK and diseases modulated by the MEK cascade in mammals, and wherein the MEK inhibitor is a compound according to Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R9, R10, R11, R12, R13 and R14 are independently selected from: hydrogen, halogen, cyano, nitro, azido, \u2014OR3, \u2014NR4C(O)OR6, \u2014OC(O)R3, \u2014NR4S(O)jR6, \u2014S(O)jNR3R4 \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6, \u2014S(O)jR6, \u2014NR4C(O)R3, \u2014C(O)NR3R4, \u2014NR5C(O)NR3R4, \u2014NR5C(NCN)NR3R4, \u2014NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, or \u2014S(O)j(C1-C6 alkyl);
provided that R12 is not OH, and R13, R14 are not C1-C10 alkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or C3-C10 cycloalkylalkyl, where each alkyl, alkenyl, alkynyl and cycloalkyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R4 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R5 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R6 is selected from trifluoromethyl, C1-C10 alkyl or C3-C10 cycloalkyl;
W is selected from \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15, \u2014C(O)NR4S(O)jR6, \u2014C(O)NR4NR4R15, \u2014NR\u2032C(O)R\u2032, \u2014NR\u2032S(O)jR\u2032,\u2014NRC(O)NR\u2032R\u2033, NR\u2032S(O)jNR\u2032R\u2033, or \u2014C(O)NR4NR4C(O)R15;
provided that W is not \u2014C(O)OH;
R15 is independently selected from: hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, trihalomethyl, O\u2014C1-C4 alkyl or NR\u2032R\u2033;
R\u2032 and R\u2033 are independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl and arylalkyl;
X is N or N+O\u2212; and
j is 1 or 2, with the proviso that 3-Phenylamino-isonicotinic acid methyl ester and 3-Oxo-3-(3-phenylamino-pyridin-4-yl)-propionic acid ethyl ester are not included.
2. The method according to claim 1, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi’s sarcoma.
3. The method according to claim 2, wherein the disease is cancer or inflammation.
4. The method according to claim 2, wherein the cancer is selected from the group consisting of ovarian, breast, lung, pancreatic, prostate, colon, melanoma and epidermoid cancer.
5. The method according to claim 3, wherein the inflammation is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
6. A method of treating a subject with a hyperproliferative disease comprising administering to the subject an effective amount of a pharmaceutical composition comprising an MEK inhibitor and a pharmaceutically acceptable excipient, wherein the hyperproliferative disease is related to the hyperactivity of MEK and diseases modulated by the MEK cascade in mammals, and wherein the MEK inhibitor is a compound of Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R9, R10, R11, R12, R13 and R14 are independently selected from: hydrogen, halogen, cyano, nitro, azido, \u2014OR3, \u2014NR4C(O)OR6, \u2014OC(O)R3, \u2014NR4S(O)jR6, \u2014S(O)jNR3R4 \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6,\u2014S(O)jR6 , \u2014NR4C(O)R3, \u2014C(O)NR3R4, \u2014NR5C(O)NR3R4, \u2014NR5C(NCN)NR3R4, \u2014NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, or \u2014S(O)j(C1-C6 alkyl);
provided that R12 is not OH, and R13, R14 are not C1-C10 alkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or C3-C10 cycloalkylalkyl, where each alkyl, alkenyl, alkynyl and cycloalkyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R4 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R5 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R6 is selected from trifluoromethyl, C1-C10 alkyl or C3-C10 cycloalkyl;
W is selected from \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15, \u2014C(O)NR4S(O)jR6, \u2014C(O)NR4NR4R15, \u2014NR\u2032C(O)R\u2032, \u2014NR\u2032S(O)jR\u2032, \u2014NRC(O)NR\u2032R\u2033, NR\u2032S(O)jNR\u2032R\u2033, or \u2014C(O)NR4NR4C(O)R15;
provided that W is not \u2014C(O)OH;
R15 is independently selected from: hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, trihalomethyl, O\u2014C1-C4 alkyl or NR\u2032R\u2033;
R\u2032 and R\u2033 are independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl and arylalkyl;
X is N or N+O\u2212; and
j is 1 or 2, with the proviso that 3-Phenylamino-isonicotinic acid methyl ester and 3-Oxo-3-(3-phenylamino-pyridin-4-yl)-propionic acid ethyl ester are not included.
7. The method according to claim 6, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi’s sarcoma.
8. The method according to claim 7, wherein the disease is cancer or inflammation.
9. The method according to claim 7, wherein the cancer is selected from the group consisting of ovarian, breast, lung, pancreatic, prostate, colon, melanoma and epidermoid cancer.
10. The method according to claim 8, wherein the inflammation is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
11. A method of treating a subject with a hyperproliferative disease comprising administering to the subject an effective amount of a MEK inhibitor, wherein the hyperproliferative disease is cancer, and wherein the MEK inhibitor is a compound according to Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R9, R10, R11, R12, R13 and R14 are independently selected from: hydrogen, halogen, cyano, nitro, azido, \u2014OR3, \u2014NR4C(O)OR6, \u2014OC(O)R3,\u2014NR4S(O)jR6, \u2014S(O)jNR3R4, \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6, \u2014S(O)jR6, \u2014NR4C(O)R3, \u2014C(O)NR3R4, \u2014NR5C(O)NR3R4, \u2014NR5C(NCN)NR3R4, \u2014NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, or \u2014S(O)j(C1-C6 alkyl);
provided that R12 is not OH, and R13, R14 are not C1-C10 alkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or C3-C10 cycloalkylalkyl, where each alkyl, alkenyl, alkynyl and cycloalkyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R4 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R5 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R6 is selected from trifluoromethyl, C1-C10 alkyl or C3-C10 cycloalkyl;
W is selected from \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15, \u2014C(O)NR4S(O)jR6, \u2014C(O)NR4NR4R15, \u2014NR\u2032C(O)R\u2032, \u2014NR\u2032S(O)jR\u2032, \u2014NRC(O)NR\u2032R\u2033, NR\u2032S(O)jNR\u2032R\u2033, or \u2014C(O)NR4NR4C(O)R15;
provided that W is not \u2014C(O)OH;
R15 is independently selected from: hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, trihalomethyl, O\u2014C1-C4 alkyl or NR\u2032R\u2033;
R\u2032 and R\u2033 are independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl and arylalkyl;
X is N or N+O\u2212; and
j is 1 or 2, with the proviso that 3-Phenylamino-isonicotinic acid methyl ester and 3-Oxo-3-(3-phenylamino-pyridin-4-yl)-propionic acid ethyl ester are not included.
12. The method according to claim 11, wherein the cancer is selected from the group consisting of ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
13. The method according to claim 11, wherein the MEK inhibitor is provided in a pharmaceutical composition comprising the MEK inhibitor and a pharmaceutically acceptable excipient.
14. A method of inhibiting hyperactivity of MEK in a cell, comprising administering to the cell an effective amount of a MEK inhibitor, wherein the MEK inhibitor is a compound according to Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R9, R10, R11, R12, R13 and R14 are independently selected from: hydrogen, halogen, cyano, nitro, azido, \u2014OR3, \u2014NR4C(O)OR6, \u2014OC(O)R3, \u2014NR4S(O)jR6, \u2014S(O)jNR3R4, \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6, \u2014S(O)jR6, \u2014NR4C(O)R3, \u2014C(O)NR3R4, \u2014NR5C(O)NR3R4, \u2014NR5C(NCN)NR3R4, \u2014NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, or \u2014S(O)j(C1-C6 alkyl);
provided that R12 is not OH, and R13, R14 are not C1-C10 alkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or C3-C10 cycloalkylalkyl, where each alkyl, alkenyl, alkynyl and cycloalkyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R4 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R5 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R6 is selected from trifluoromethyl, C1-C10 alkyl or C3-C10 cycloalkyl;
W is selected from \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15, \u2014C(O)NR4S(O)jR6, \u2014C(O)NR4NR4R15, \u2014NR\u2032C(O)R\u2032, \u2014NR\u2032S(O)jR\u2032, \u2014NRC(O)NR\u2032R\u2033, NR\u2032S(O)jNR\u2032R\u2033, or \u2014C(O)NR4NR4C(O)R15;
provided that W is not \u2014C(O)OH;
R15 is independently selected from: hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, trihalomethyl, O\u2014C1-C4 alkyl or NR\u2032R\u2033;
R\u2032 and R\u2033 are independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl and arylalkyl;
X is N or N+O\u2212; and
j is 1 or 2, with the proviso that 3-Phenylamino-isonicotinic acid methyl ester and 3-Oxo-3-(3-phenylamino-pyridin-4-yl)-propionic acid ethyl ester are not included.
15. The method according to claim 1, wherein:
R1, R2, R9, R10, R11, R12, R13 and R14 are independently selected from hydrogen, halogen, cyano, nitro, azido, \u2014OR3, \u2014NR4C(O)OR6, \u2014OC(O)R3, \u2014NR4S(O)jR6, \u2014S(O)jNR3R4, \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6, S(O)jR6, \u2014NR4C(O)R3, \u2014C(O)NR3R4, \u2014NR5C(O)NR3R4, \u2014NR5C(NCN)NR3R4, \u2014NR3R4, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl or \u2014S(O)j(C1-C6 alkyl);
provided that R12 is not OH, and R13, R14 are not C1-C10 alkyl;
R3 is selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl or C3-C10 cycloalkylalkyl, where each alkyl, alkenyl, alkynyl and cycloalkyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R4 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R5 is selected from hydrogen or C1-C6 alkyl, whereby alkyl may be unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro or trihalomethyl;
R6 is selected from trifluoromethyl, C1-C10 alkyl or C3-C10 cycloalkyl;
W is \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15 or \u2014C(O)NR4S(O)jR6;
provided that W is not C(O)OH;
R15 is independently selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or substituted with primary amino, aminocarbonyl, carboxyl, cyano, halogen, hydroxy, nitro, trihalomethyl, O\u2014C1-C4 alkyl or NR\u2032R\u2033;
R\u2032 and R\u2033are independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl or arylalkyl;
X is N or N+O\u2212; and
j is 1 or 2.
16. The method according to claim 1, wherein:
R1, R2, R9 and R11 are independently selected from hydrogen, halo, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, cyano, nitro, OR3 or NR3R4, where each alkyl, alkenyl, alkynyl, cycloalkyl is optionally substituted with one to five halogens;
R10 and R12 are independently selected from hydrogen, halo, C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, C2-C10 alkynyl, cyano, nitro, azido, NR4SO2R6, SO2NR3R4, SO2R6, C(O)NR3R4, \u2014S(O)jNR4C(O)R3, \u2014C(O)NR4S(O)jR6, OR3, NR3R4 or \u2014S(C1-C2 alkyl) substituted with 1 to 5 F;
R13 and R14 are independently selected from H, F, Cl, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl, where each alkyl, alkenyl, cycloalky, alkynyl is optionally substituted with one to five halogens;
W is \u2014C(O)OR15, \u2014C(O)NR4R15, \u2014C(O)NR4OR15, \u2014C(O)(C2-C10 alkyl) or \u2014C(O)NR4S(O)jR6;
R15 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkenyl or C4-C6 cycloalkylalkyl, where alkyl or alkenyl is optionally substituted by 1 or 2 of OH, O\u2014C1-C4 alkyl or NR\u2032R\u2033; and
R\u2032 and R\u2033 are each independently selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, aryl or arylalkyl.
17. The method according to claim 1, wherein:
R1 is independently selected from H and F;
R2 is independently selected from hydrogen, F, Cl or Me, where the methyl group is optionally substituted with one to three fluorines;
R9 is independently selected from H, F or Cl;
R10 is independently selected from H, F, Cl, Br, nitro, Me or OMe, where the methyl groups are optionally substituted with one to three fluorines, SO2NR3R4 or C(O)NR3R4, wherein R3 and R4 are independently C1-C6 alkyl, optionally substituted by 1 or 2 alkyl amino or O-alkyl, or R3 and R4 taken together form a cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by 1 or 2 alkyl amino or O-alkyl;
R11 is independently selected from H, F, Cl, Br, Me or OMe, where the methyl groups are optionally substituted with one to three fluorines;
R12 is independently selected from H, F, Cl, Br, nitro, Me, SCF3, SCHF2, SCH2F, SO2NR3R4, C(O)NR3R4 or OMe, where the methyl groups are optionally substituted with one to three fluorines, wherein R3 and R4 are independently C1-C6 alkyl, optionally substituted by 1 or 2 alkyl amino or O-alkyl, or R3 and R4 taken together form a cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by 1 or 2 alkyl amino or O-alkyl;
R13 is independently selected from H and F;
R14 is independently selected from H and F;
W is \u2014C(O)NR4OR15; and
R15 is C1-C4 alkyl or C1-C4 alkenyl optionally substituted with 1 to 3 substituents OH, O-Me, NH2, N(methyl)2 or N(ethyl)2.
18. The method according to claim 1, wherein:
W is \u2014C(O)NR4OR15;
R4 is hydrogen;
R15 is selected from C1-C4 alkyl or C1-C4 alkenyl that may be further substituted by 1 or 2 of OH, O\u2014C1-C4 alkyl or NR\u2032R\u2033; and
R\u2032 and R\u2033 are independently hydrogen, methyl or ethyl.